United States-based Cancer Genetics has signed a contract with NovellusDx, a precision oncology company, it was reported yesterday.
According to the contract, NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to around 49% of the equity of Cancer Genetics on a fully diluted basis.
Cancer Genetics will be the surviving entity and expects to remain listed on the Nasdaq Stock Market.
This deal is intended to integrate Cancer Genetics' scale, expansive test portfolio and broad data set related to tumour biology, cultivated over more than a decade, with NovellusDx's proprietary technology and machine learning capabilities to form a leading, oncology-focused precision medicine company. The goal of the integrated company is to accelerate and improve therapeutic development, effectively matching patients to targeted therapies to improve treatment success rates for biopharma companies.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886